EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
- Pivotal emu™ trial exceeds 230 participants toward a 300-patient primary cohort
- Acute ischaemic stroke detection feature to be discussed with the FDA
- First Responder mobile stroke unit study completes Stage 1 usability objectives
- Production-equivalent First Responder units targeted for H1 CY27
- Cash rises to $18.1 million after R&D rebate and grant receipts
Pivotal Trial Moves Toward Its 300-Patient Target
EMVision Medical Devices Limited (ASX:EMV) has moved its central clinical program into the final stretch, with recruitment in the emu™ Pivotal Trial exceeding 230 participants by early October. Most of those patients are now contributing to the primary analysis cohort, which is designed to enrol about 300 suspected stroke participants, split evenly between people with and without intracranial haemorrhage.
The trial is intended to support a future FDA De Novo submission for the bedside brain scanner, with a primary objective of demonstrating sensitivity and specificity above 80% for detecting intracranial bleeding. EMVision remains blinded to certain study data until recruitment is complete and the results have undergone independent analysis. The company is targeting completion of primary cohort enrolment in early calendar 2027, with data lock and readout expected around mid-year, although the timetable remains dependent on recruitment and regulatory feedback. The latest progress follows the 200-patient trial milestone, reported in August.
Ischaemic Stroke Feature Adds a Second FDA Question
EMVision is also seeking to broaden what emu™ could detect from its first FDA-cleared release. The company has defined the intended use and performance thresholds for an acute ischaemic stroke feature, which would identify strokes caused by a blocked blood vessel, and plans to discuss a trial amendment with the FDA through an upcoming Q-Sub process.
The proposed approach would use ischaemic stroke cases already being collected in the pivotal study, with only a modest increase in sample size anticipated. That could expand the commercial and clinical proposition, but it is not yet an approved regulatory pathway or a diagnostic result: FDA feedback is still pending, the trial remains blinded and the feature must meet its defined performance requirements. The company says the issue is particularly relevant in hospitals without round-the-clock access to advanced imaging such as CT perfusion or MRI.
First Responder Device Passes Roadside Usability Test
The pre-hospital program has cleared another engineering and workflow checkpoint. Stage 1 of the Mobile Stroke Unit Study with Ambulance Victoria and The Royal Melbourne Hospital met its primary usability and workflow objectives, following an earlier Royal Flying Doctor Service study that tested the prototype across 14 air transfers.
Those studies have informed a production-equivalent First Responder design with fewer components and materially lower weight than earlier prototypes. EMVision is targeting completion of the updated units in the first half of calendar 2027, ahead of data collection, further mobile stroke unit work and a planned 510(k) validation pathway using emu™ as the predicate device. The program's next challenge is therefore less about demonstrating that the prototype can operate in demanding settings and more about producing the clinical and regulatory evidence required for market access. The latest milestone builds on the roadside feasibility study, which involved a 10-participant mobile stroke unit exercise.
Cash Position Strengthened by Non-Dilutive Funding
EMVision finished the quarter with $18.091 million in cash and cash equivalents, up from $17.104 million three months earlier. The improvement was driven by a $4.296 million R&D tax incentive rebate, a $650,000 Industry Growth Program payment and a $307,000 CRC-P grant payment, rather than customer receipts. The company also reported $3.7 million of funding remaining under its current grant programs.
Underlying spending included $1.004 million on research and development, $2.372 million in staff costs and $833,000 in corporate administration. Net operating cash flow was positive at $1.008 million for the quarter, but that figure should be read alongside the timing of the tax and grant receipts. A non-binding memorandum with the Australian Stroke Alliance is aimed at pursuing further non-dilutive funding for pre-hospital stroke diagnosis, building on the existing MRFF collaboration.
The Next Inflection Point Is Trial Readout
EMVision now has several linked milestones approaching: FDA engagement on the ischaemia endpoint, completion of the 300-participant primary cohort, independent analysis of the pivotal data and construction of the production-equivalent First Responder units. The company's stated ambition is to move from clinical-stage development toward commercialisation, but that transition still depends on evidence and regulatory decisions that have yet to arrive.
Bottom Line?
The cash balance gives EMVision room to pursue its next milestones, but the decisive test remains the blinded pivotal readout and the FDA response to the expanded endpoint.
Questions in the middle?
- Will the FDA accept the proposed acute ischaemic stroke endpoint within the existing pivotal trial design?
- Can EMVision complete the 300-patient primary cohort on its early 2027 target without a material increase in trial scope or cost?
- Will the lighter production-equivalent First Responder units reproduce prototype usability while generating evidence sufficient for the planned 510(k) pathway?